GUPTA, D. L.; MEHER, J.; GIRI, A. K.; SHUKLA, A. K.; MOHAPATRA, E.; RUIKAR, M. M.; RAO, D. RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients. Drug Target Insights, [S. l.], v. 18, n. 1, p. 20–26, 2024. DOI: 10.33393/dti.2024.3059. Disponível em: Acesso em: 20 jul. 2024.